U.S., June 14 -- ClinicalTrials.gov registry received information related to the study (NCT07020260) titled 'The PACMAN-Hu19 Trial: a Study of the Safety and Feasibility of Locally Produced, CD19-targeted and Human CAR T-cell Therapy in Children and Young Adults With Relapsed or Refractory B-cell Malignancies' on Feb. 26.
Brief Summary: PACMAN is a phase I/II single arm, open-label, multi-center study evaluating the safety of human CD19 CAR-T (huCAR19) produced locally using the Miltenyi Prodigy in children, adolescents and young adults with relapsed/refractory CD19+ hematological malignancies for whom no standard of care treatment is available.
Study Start Date: Sept. 01, 2025
Study Type: INTERVENTIONAL
Condition:
Leukemia
Lymphoma
I...